An initiative to enter the pharmaceutical CDMO business through the acquisition of 滋賀県製薬, with a target of ¥20 billion in pharmaceutical business sales in 2030. It covers business expansion by combining the acquired company’s dosage-form capabilities and customer base with the company’s own formulation design, quality control, automation and digital transformation capabilities.